Erasca’s RAS-Targeting Pill Shows Strong Early Results in Pancreatic and Lung Cancer Trials
Erasca’s RAS-targeting pill, ERAS-0015, reduced tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer pa...
Erasca’s RAS-targeting pill, ERAS-0015, reduced tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer pa...
Erasca, valued at nearly $7 billion, is racing to prove its pan-RAS inhibitor ERAS-0015 could rival Revolution Medicines in pancreatic cancer treatmen...